organization

BIOEMTECH

BIOEMISSION TECHNOLOGY SOLUTIONS IKE
6 projects, page 1 of 2
  • project . 2016 - 2019
    Funder: EC Project Code: 691203
    Overall Budget: 432,000 EURFunder Contribution: 432,000 EUR
    Open Access mandate for Publications
    Partners: INSERM, GSTFT, UNIVERSITY OF PATRAS, LIBRA MLI LTD., UBO, BIOEMTECH

    The main objective of ERROR is to develop a new software tool, which will offer to the clinician the possibility to assess alternative imaging and therapeutic protocols, in real time, in silico, in order to minimize patient dose, while maintaining image quality of thera...

  • project . 2018 - 2021
    Funder: EC Project Code: 764837
    Overall Budget: 2,548,260 EURFunder Contribution: 2,548,260 EUR
    Open Access mandate for Publications and Research Data
    Partners: PWR, University of Coimbra, BIOEMTECH, University of Neuchâtel, TRINITY COLLEGE DUBLIN, UvA, University of Limoges

    The development of active compounds that can efficiently fight microbial infections and cancer are of utmost importance for food security and human health, two main challenges for Europe. Tetrapyrrolic photosensitizers (PS) are good candidates to meet these expectations...

  • project . 2015 - 2019
    Funder: EC Project Code: 645757
    Overall Budget: 472,500 EURFunder Contribution: 472,500 EUR
    Open Access mandate for Publications
    Partners: National Centre of Scientific Research Demokritos, BIOEMTECH, BONUS THERAPEUTIC LTD, CNR, University of Leeds, CSIC, University of Mons, Bioimag

    The main objective of VIVOIMAG is to develop bone implants including a new contrast agent sensitive to enzymatic activity of metaloproteases, which will permit for the first time to follow the integration and cell differentiation activity in bone tissue bioreactors in v...

  • project . 2018 - 2022
    Funder: EC Project Code: 801159
    Overall Budget: 3,799,370 EURFunder Contribution: 3,799,370 EUR
    Open Access mandate for Publications
    Partners: UM, IN SRL, ERASMUS MC, University of Basel, BIOEMTECH, CITC Ltd, CNR, R4L

    Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread ...

  • project . 2017 - 2021
    Funder: EC Project Code: 720834
    Overall Budget: 6,094,780 EURFunder Contribution: 6,094,780 EUR
    Open Access mandate for Publications
    Partners: CITC Ltd, CNR, SARD, IN SRL, FINCERAMICA, Charité Universitätsmedizin Berlin, Imperial, PLUMESTARS, BIOEMTECH, L.I.F.E. ITALIA SRL...

    The incidence of Cardiovascular Disease (CD) claims worldwide 17.1 million lives a year, with an estimated 31% of all deaths globally and a EU cost of 139 billion euros. Up to 40% of all deaths occur among the elderly. In spite of all medical efforts, the 5-year mortali...

6 projects, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue